CONTENTS:

• Long-term overuse of corticosteroids in the real-world treatment of patients with immune thrombocytopenia
• ITP patient perceptions on splenectomy outcomes

 
CONTENTS:

• FDA Approves Romiplostim (N-Plate) as a Treatment Option for Pediatric Patients with Immune Thrombocytopenia
• Berberine May Offer ITP Patients Suffering from Corticosteroid Resistance Induced by Gut Microbiota Imbalance a New Option for Therapy

 
CONTENTS:

• Retrospective Study Finds That The Combination Therapy of Rituximab and Cyclophosphamide Displays Increased Therapeutic Effects Compared To Each Drugs Individual Therapeutic Effects on Patients Suffering From Refractory ITP
• Chidamide Study Displays Potential For Novel Therapies and Multiple Pathways For ITP Intervention

 
CONTENTS:

• Increased Monitoring Should Be Utilized When Receiving Immune Checkpoint Inhibitors
• Posttransfusion Purpura with Antibodies Against Human Platelet Antigen-4a following Checkpoint Inhibitor Therapy: a Case Report and Review of the Literature

CONTENTS:

• COVID-19 vaccines and ITP: Should patients be vaccinated?
• Anxiety In Adult Patients Living With ITP Stratified Across Different Treatment Types and Groups: A Survey study by PDSA
• Importance Of Glycoside Residues On Haemostatsis of Patients With Immune Thrombocytopenia
• Tapering Thrombopoietin Receptor Agonists In Primary Immune Thrombocytopenia: Recommendations Based On The RAND/UCLA Modified Delphi Panel Method

CONTENTS:

• Phase 1/2 Trial Shows Promise For Rilzabrutinib In Patients With ITP
• Fostamatinib Is An Effective Second-Line Therapy In Patients With Immune Thrombocytopenia
• Health Canada Approves TAVALISSE For The Treatment Of Adults With Chronic Immune Thrombocytopenia

In light of the COVID-19 global pandemic, the 25th Congress of the European Hematology Association (EHA) scheduled to take place in Frankfurt, Germany switched their annual meeting to a virtual meeting held online between June 11-21, 2020. PDSA staff and members of the PDSA medical advisory board participated in this prestigious meeting by submitting multiple abstracts that were accepted in e-poster format. PDSA President and CEO, Caroline Kruse, and Research Coordinator, Alexandra Kruse, are authors on all of the following abstracts.

CONTENTS:

• Higher Symptom Burden In Patients With Immune Thrombocytopenia Experiencing Fatigue: Results From The ITP World Impact Survey (I-WISH)
• Patient’s Reported Perceptions On Satisfaction With Immune Thrombocytopenia Treatments: Results From The ITP World Impact Survey (I-WISH)

CONTENTS:

• Perioperative Oral Eltrombopag Versus Intravenous Immunoglobulin In Patients With Immune Thrombocytopenia: A Non-Inferiority, Multicenter, Randomized Trial
• NIH Launches Trial of Rigel Drug for Severe COVID-19 and Octapharma launches trial for intravenous immunoglobulin (IVIG) as Potential Treatment for COVID-19

CONTENTS:

• Fostamatinib Is An Effective Second-Line Therapy In Patients With Immune Thrombocytopenia
• A Patient’s Perspective On Impact of Immune Thrombocytopenia On Emotional Wellbeing: ITP World Impact Survey (I-WISH)

In light of the COVID-19 global pandemic, the 25th Congress of the European Hematology Association (EHA) scheduled to take place in Frankfurt, Germany switched their annual meeting to a virtual meeting held online between June 11-21, 2020. PDSA staff and members of the PDSA’s medical advisory board participated in this prestigious meeting by submitting multiple abstracts that were accepted in e-poster format. The following summaries are from two insightful e-poster abstracts presented at EHA.

CONTENTS:

• Long-Term Overuse of Corticosteroids in Patients with Immune Thrombocytopenia: A Real-World Analysis of a US Claims Database
• Mental Health and Physical Function in Pediatric Immune Thrombocytopenia (ITP): Quality of Life Data from the Platelet Disorder Support Association (PDSA) Patient Registry